11/19/20 8:00 AMNasdaq : PTCTPTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx ConferencePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at Evercore ISI 3 rd Annual HealthCONx Conference on Tuesday, December 1 st at 11:45 a.m. ET.The presentation will be webcast live on theRHEA-AIneutral
11/18/20 8:00 AMNasdaq : PTCTPTC Therapeutics Announces Key Regulatory Designations for PTC596 to Advance Treatment of Two Rare Oncology IndicationsPTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted PTC596 both Orphan Drug Designation and Fast Track designation for the potential treatment of leiomyosarcomaRHEA-AIvery positive
11/17/20 8:00 AMNasdaq : PTCTPTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease ProgramPTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a Phase 1 clinical trial to evaluate PTC518 in healthy volunteers. PTC518 was identified from PTC's splicing platform and is being developed for the treatment ofRHEA-AIneutral
11/16/20 8:00 AMNasdaq : PTCTPTC Therapeutics Highlights Data on High Disease Burden and Value of Treatment Across Two Rare DiseasesPTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of data on two rare diseases, providing new insights on the burden of Aromatic L-Amino acid Decarboxylase deficiency (AADC-d) and Duchenne muscular dystrophy caused byRHEA-AIneutral
10/29/20 4:01 PMNasdaq : PTCTPTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate UpdatePTC Therapeutics, Inc. (NASDAQ: PTCT) today announced financial results for the third quarter ending September 30, 2020 and provided a corporate update. "I am very pleased by the rapid progress that we have made this quarter with the approvalRHEA-AIpositive
10/28/20 4:30 PMNasdaq : PTCTPTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on October 23, 2020 it approved non-statutory stock options to purchase an aggregate of 18,610 shares of its common stock and 6,860 restricted stock units ("RSUs"), each representing theRHEA-AIneutral
10/28/20 8:00 AMNasdaq : PTCTPTC Therapeutics to Participate at Upcoming Virtual Investor ConferencesPTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences:Credit Suisse 29 th Annual Virtual Healthcare Conference Wednesday, November 11 th at 9:30 a.m. ETBarclaysRHEA-AIneutral
10/26/20 8:00 AMNasdaq : PTCTPTC Therapeutics Announces Initiation of a Registration-Directed Clinical Trial to Evaluate Vatiquinone in Mitochondrial EpilepsyPTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of a registration-directed Phase 2/3 clinical trial to evaluate vatiquinone (PTC743) in patients with mitochondrial epilepsy, the highly morbid condition of refractoryRHEA-AIneutral
10/22/20 8:00 AMNasdaq : PTCTPTC Therapeutics and AADC Family Network Announce First-Ever AADC Deficiency Awareness Day in MassachusettsPTC Therapeutics, Inc. (NASDAQ: PTCT) and the AADC Family Network today announced that Oct. 23, 2020, has been officially designated as the first Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Awareness Day in the State of Massachusetts,RHEA-AIneutral
10/21/20 8:33 AMNasdaq : PTCTEvrysdi(TM) (risdiplam) Continues to Make Global Progress for the Treatment of Spinal Muscular AtrophyPTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi(TM) (risdiplam) was approved in Brazil by the National Health Surveillance Agency (ANVISA) for the treatment of spinal muscular atrophy (SMA). The approval was obtained within sevenRHEA-AIvery positive
